Drugs / VK2735 Drug
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05203237 | Dec 2021 → Nov 2024 | metabolic dysfunction-associated steatohepatitis | Viking Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VK2735 Drug | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05203237 ↗ |
| Action | Activate | “VK2735, a Dual Glucagon-like Peptide-1 and Gastric Inhibitory Polypeptide Receptor Agonist” NCT05203237 ↗ |
| Route | Oral | “Escalating doses of VK2735 administered daily (PO) in healthy participants.” NCT05203237 ↗ |